83 related articles for article (PubMed ID: 23558942)
21. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
Bhowmik T; Gomes A
Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
[TBL] [Abstract][Full Text] [Related]
22. The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer.
Benesch C; Schneider C; Voelker HU; Kapp M; Caffier H; Krockenberger M; Dietl J; Kammerer U; Schmidt M
Anticancer Res; 2010 May; 30(5):1689-94. PubMed ID: 20592362
[TBL] [Abstract][Full Text] [Related]
23. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.
Kim JS; Kim HA; Seong MK; Seol H; Oh JS; Kim EK; Chang JW; Hwang SG; Noh WC
Oncotarget; 2016 Feb; 7(6):7055-65. PubMed ID: 26755645
[TBL] [Abstract][Full Text] [Related]
24. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
25. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
[TBL] [Abstract][Full Text] [Related]
26. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
Sengupta S; Schiff R; Katzenellenbogen BS
Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
[TBL] [Abstract][Full Text] [Related]
27. Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways.
Wang LJ; Han SX; Bai E; Zhou X; Li M; Jing GH; Zhao J; Yang AG; Zhu Q
Oncol Rep; 2013 Apr; 29(4):1563-9. PubMed ID: 23338782
[TBL] [Abstract][Full Text] [Related]
28. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
30. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
[TBL] [Abstract][Full Text] [Related]
31. [Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].
Han YC; Zeng XX; Wang R; Zhao Y; Li BL; Song M
Ai Zheng; 2007 Jan; 26(1):48-53. PubMed ID: 17222367
[TBL] [Abstract][Full Text] [Related]
32. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
33. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.
Pérez-Tenorio G; Stål O;
Br J Cancer; 2002 Feb; 86(4):540-5. PubMed ID: 11870534
[TBL] [Abstract][Full Text] [Related]
34. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
35. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
36. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
Brennan K; McSherry EA; Hudson L; Kay EW; Hill AD; Young LS; Hopkins AM
Oncogene; 2013 May; 32(22):2799-804. PubMed ID: 22751120
[TBL] [Abstract][Full Text] [Related]
37. IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway.
Matà R; Palladino C; Nicolosi ML; Lo Presti AR; Malaguarnera R; Ragusa M; Sciortino D; Morrione A; Maggiolini M; Vella V; Belfiore A
Oncotarget; 2016 Feb; 7(7):7683-700. PubMed ID: 26655502
[TBL] [Abstract][Full Text] [Related]
38. The level of phosphorylated Akt predominantly reflects the expressive status of CerbB2 in invasive breast cancer.
Chi Y; Zhao J; Cui SP; Jiang P; Wang HL; Zhang H; Mao JZ; Liu HJ; Hou L; Zhang B
Histol Histopathol; 2013 May; 28(5):655-61. PubMed ID: 23420345
[TBL] [Abstract][Full Text] [Related]
39. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
[TBL] [Abstract][Full Text] [Related]
40. Effects of Intermittent Hypoxia on Expression of Glucose Metabolism Genes in MCF7 Breast Cancer Cell Line.
Jarrar Y; Zihlif M; Al Bawab AQ; Sharab A
Curr Cancer Drug Targets; 2020; 20(3):216-222. PubMed ID: 31738135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
